@NP	Neuronal Populations Capable of Regeneration	1
@NP	Neuronal Populations	1
@NP	Regeneration	33
@NP	a Combined Treatment	56
@NP	Rats with Spinal Cord Transection ROMANA VAVREK ,1 DAMIEN D.	80
@NP	Rats	80
@NP	Spinal Cord Transection ROMANA VAVREK ,1 DAMIEN D.	90
@NP	PEARSE ,2	141
@NP	KARIM FOUAD1	154
@NP	ABSTRACT Axonal regeneration	168
@NP	spinal cord injury -LRB- SCI -RRB- in adult mammals	203
@NP	spinal cord injury -LRB- SCI -RRB-	203
@NP	spinal cord injury	203
@NP	SCI	223
@NP	adult mammals	231
@NP	inhibitors associated with myelin and the glial scar	259
@NP	inhibitors	259
@NP	myelin and the glial scar	286
@NP	myelin	286
@NP	the glial scar	297
@NP	these inhibitors	325
@NP	a combined approach	343
@NP	We	381
@NP	complete SCI	429
@NP	rats , a combination of bridging the lesion with Schwann cell -LRB- SC -RRB- --	445
@NP	rats	445
@NP	a combination of bridging the lesion with Schwann cell -LRB- SC -RRB-	451
@NP	a combination	451
@NP	the lesion	477
@NP	Schwann cell -LRB- SC -RRB-	493
@NP	Schwann cell	493
@NP	SC	507
@NP	guidance channels , olfactory ensheathing glia implantation , and chondroitinase	518
@NP	guidance channels	518
@NP	olfactory ensheathing glia implantation	537
@NP	chondroitinase	582
@NP	ABC delivery	597
@NP	regeneration of serotonergic fibers	619
@NP	regeneration	619
@NP	serotonergic fibers	635
@NP	the lumbar spinal cord	660
@NP	addition	687
@NP	this combinatory treatment	697
@NP	locomotor recovery	747
@NP	these findings	781
@NP	we	797
@NP	this combined treatment	809
@NP	fibers other than serotonergic axons	851
@NP	fibers	851
@NP	serotonergic axons	869
@NP	the caudal spinal cord	917
@NP	this experiment	944
@NP	we	961
@NP	the retrograde tracer FluoroGold -LRB- FG -RRB-	973
@NP	the retrograde tracer FluoroGold	973
@NP	FG	1007
@NP	the spinal cord caudal	1016
@NP	a complete transection in a control and a treated group	1042
@NP	a complete transection	1042
@NP	a control and a treated group	1068
@NP	a control	1068
@NP	a treated group	1082
@NP	FG-positive cells rostral	1099
@NP	the lesion	1128
@NP	the brainstem of animals in the treated group	1146
@NP	the brainstem	1146
@NP	animals in the treated group	1163
@NP	animals	1163
@NP	the treated group	1174
@NP	axons	1204
@NP	the SC bridge	1241
@NP	the caudal spinal cord	1264
@NP	rats	1296
@NP	cells	1313
@NP	the reticulospinal nuclei , vestibular nuclei , and the raphe nucleus	1322
@NP	the reticulospinal nuclei	1322
@NP	vestibular nuclei	1349
@NP	the raphe nucleus	1372
@NP	the spinal cord	1404
@NP	Cell numbers	1421
@NP	highest in the thoracic spinal cord and the lateral vestibular nucleus	1439
@NP	highest	1439
@NP	the thoracic spinal cord and the lateral vestibular nucleus	1450
@NP	the thoracic spinal cord	1450
@NP	the lateral vestibular nucleus	1479
@NP	the mechanisms	1523
@NP	the superior capability of these cell populations	1542
@NP	the superior capability	1542
@NP	these cell populations	1569
@NP	valuable clues	1618
@NP	the design of future treatment approaches	1636
@NP	the design	1636
@NP	future treatment approaches	1650
@NP	INTRODUCTION AXONS OF THE MAMMALIAN CENTRAL NERVOUS SYSTEM -LRB- CNS -RRB-	1680
@NP	INTRODUCTION AXONS OF THE MAMMALIAN CENTRAL NERVOUS SYSTEM	1680
@NP	INTRODUCTION AXONS	1680
@NP	THE MAMMALIAN CENTRAL NERVOUS SYSTEM	1702
@NP	CNS	1740
@NP	following injury	1770
@NP	This lack of regeneration	1788
@NP	This lack	1788
@NP	regeneration	1801
@NP	a combination of factors	1833
@NP	a combination	1833
@NP	factors	1850
@NP	the inhibitory character	1869
@NP	the astrocytic scar	1897
@NP	the lesion site	1931
@NP	myelin-associated inhibitors	1948
@NP	insufficient neurotrophic support	1982
@NP	Schwab and Bartholdi	2017
@NP	1996	2039
@NP	the inhibitory environment of the injured spinal cord	2058
@NP	the inhibitory environment	2058
@NP	the injured spinal cord	2088
@NP	a growth	2127
@NP	permissive bridge for regenerating axons	2136
@NP	permissive bridge	2136
@NP	regenerating axons	2158
@NP	we	2178
@NP	a combinatory therapy of a Schwann cell -LRB- SC -RRB-	2200
@NP	a combinatory therapy	2200
@NP	a Schwann cell	2225
@NP	SC	2241
@NP	guidance channel , injections of olfactory-ensheathing glia -LRB- OEG -RRB-	2256
@NP	guidance channel	2256
@NP	injections of olfactory-ensheathing glia -LRB- OEG -RRB-	2274
@NP	injections	2274
@NP	olfactory-ensheathing glia -LRB- OEG -RRB-	2288
@NP	olfactory-ensheathing glia	2288
@NP	OEG	2316
@NP	the rostral and caudal stumps of the host spinal cord	2326
@NP	the rostral	2326
@NP	caudal stumps of the host spinal cord	2342
@NP	caudal stumps	2342
@NP	the host spinal cord	2359
@NP	intrathecal delivery of chondroitinase	2385
@NP	intrathecal delivery	2385
@NP	chondroitinase	2409
@NP	ABC -LRB- cABC -RRB-	2424
@NP	ABC	2424
@NP	cABC	2429
@NP	the bridge/stump interfaces -LRB- Fouad et al. , 2005 -RRB-	2438
@NP	the bridge/stump interfaces	2438
@NP	Fouad	2467
@NP	et al. , 2005	2473
@NP	et al.	2473
@NP	2005	2481
@NP	This combined therapy	2488
@NP	significantly improved hind limb function	2522
@NP	significantly improved hind limb	2522
@NP	function	2555
@NP	the numbers of myelinated axons	2575
@NP	the numbers	2575
@NP	myelinated axons	2590
@NP	the SC bridges	2614
@NP	regeneration of serotonergic fibers	2643
@NP	regeneration	2643
@NP	serotonergic fibers	2659
@NP	the lumbar spinal cord	2684
@NP	the lack of correlation between recovery and regenerated serotonergic fibers	2717
@NP	the lack	2717
@NP	correlation	2729
@NP	recovery	2749
@NP	serotonergic fibers	2774
@NP	other fiber types	2814
@NP	regeneration	2848
@NP	a shortcoming of the study	2868
@NP	a shortcoming	2868
@NP	the study	2885
@NP	Fouad	2898
@NP	et al. -LRB- 2005 -RRB-	2904
@NP	et al.	2904
@NP	2005	2912
@NP	the use of an anterograde tracer	2922
@NP	the use	2922
@NP	an anterograde tracer	2933
@NP	the motor cortex only , which failed to provide evidence for that possibility	2960
@NP	the motor cortex only	2960
@NP	evidence	3007
@NP	that possibility	3020
@NP	The goal of the current study	3038
@NP	The goal	3038
@NP	the current study	3050
@NP	the combined treatment	3092
@NP	neuronal populations	3128
@NP	the tissue bridge	3175
@NP	the caudal spinal cord	3202
@NP	a retrograde tracer caudal	3239
@NP	the injury	3269
@NP	METHODS All procedures were performed according to Fouad	3282
@NP	METHODS	3282
@NP	All procedures	3290
@NP	Fouad	3333
@NP	et al.	3339
@NP	2005	3347
@NP	adult female Fischer rats -LRB- Charles River , Wilmington , MA -RRB-	3360
@NP	adult female Fischer rats	3360
@NP	Charles River	3387
@NP	Wilmington	3402
@NP	MA	3414
@NP	The experiment	3419
@NP	local authorities	3450
@NP	SC and OEGs	3469
@NP	Fouad et al. , 2005	3520
@NP	Fouad	3520
@NP	et al.	3526
@NP	2005	3534
@NP	SCs	3551
@NP	sciatic nerves of adult female Fischer rats	3574
@NP	sciatic nerves	3574
@NP	adult female Fischer rats	3592
@NP	cultures of OEG	3655
@NP	cultures	3655
@NP	OEG	3667
@NP	the nerve fiber layer of the olfactory bulb of adult female Fischer rats	3690
@NP	the nerve fiber layer	3690
@NP	the olfactory bulb of adult female Fischer rats	3715
@NP	the olfactory bulb	3715
@NP	adult female Fischer rats	3737
@NP	a procedure modified from one described previously	3769
@NP	a procedure	3769
@NP	one described previously	3795
@NP	one	3795
@NP	Ramón-Cueto	3821
@NP	et al. , 1998	3833
@NP	et al.	3833
@NP	1998	3841
@NP	SCs or OEG	3857
@NP	DMEM/F -12 medium	3886
@NP	transplantation	3911
@NP	OEG	3928
@NP	them	3959
@NP	the dishes	3969
@NP	the cells	3985
@NP	a hemocytometer	4014
@NP	SCs	4031
@NP	a 60:40 -LRB- v/v -RRB- solution	4055
@NP	DMEM/F -12 / Matrigel -LRB- BD Biosciences , San Jose , CA -RRB-	4081
@NP	DMEM/F -12 / Matrigel	4081
@NP	DMEM/F -12	4081
@NP	Matrigel	4091
@NP	BD Biosciences	4101
@NP	San Jose	4117
@NP	CA	4127
@NP	Each animal	4160
@NP	a total of 5 x 10 ^ 6 SCs	4181
@NP	a total of 5	4181
@NP	a total	4181
@NP	5	4192
@NP	10 ^ 6 SCs	4196
@NP	10 ^	4196
@NP	6 SCs	4199
@NP	transplantation	4209
@NP	OEG	4226
@NP	aliquots of 4 µL of DMEM/F -12 medium	4250
@NP	aliquots	4250
@NP	4 µL of DMEM/F -12 medium	4262
@NP	4 µL	4262
@NP	DMEM/F -12 medium	4270
@NP	4	4298
@NP	10 ⌃	4302
@NP	5 cells	4305
@NP	spinal cord injection	4332
@NP	the surgery	4359
@NP	animals	4372
@NP	Hypnorm	4403
@NP	120 µL per 200 g bw ; Janssen Pharmaceutics , Beerse , Belgium	4412
@NP	120 µL	4412
@NP	200 g bw ; Janssen Pharmaceutics , Beerse , Belgium	4423
@NP	200 g bw	4423
@NP	Janssen Pharmaceutics , Beerse , Belgium	4433
@NP	Janssen Pharmaceutics	4433
@NP	Beerse , Belgium	4456
@NP	Midazolam	4477
@NP	0.75 mg	4488
@NP	150 µL/200 g bwt ; s.c. ; 750 µL total volume	4499
@NP	150 µL/200 g bwt	4499
@NP	s.c. ; 750 µL total volume	4517
@NP	s.c.	4517
@NP	750 µL total volume	4523
@NP	750 µL	4523
@NP	total volume	4530
@NP	H2O ; Sabex , Boucherville , Quebec , Canada	4554
@NP	H2O	4554
@NP	Sabex , Boucherville , Quebec , Canada	4559
@NP	a laminectomy of the thoracic 7 -- 9 vertebral segment	4603
@NP	a laminectomy of the thoracic 7	4603
@NP	a laminectomy	4603
@NP	the thoracic 7	4620
@NP	9 vertebral segment	4635
@NP	a 4-mm region of spinal cord encompassing Th8	4656
@NP	a 4-mm region	4656
@NP	spinal cord encompassing Th8	4673
@NP	spinal cord	4673
@NP	Th8	4698
@NP	the treated group	4718
@NP	a volume of 1 µL containing ≈ 105 OEG in DMEM/F -12	4737
@NP	a volume	4737
@NP	1 µL containing ≈ 105 OEG in DMEM/F -12	4749
@NP	1 µL	4749
@NP	≈ 105 OEG	4765
@NP	DMEM/F -12	4777
@NP	each stump	4804
@NP	the spinal cord stumps	4822
@NP	2 mm	4859
@NP	a 6-mmlong hollow , semipermeable 60:40 polyacrylonitrile	4869
@NP	60:40	4902
@NP	polyvinylchloride copolymer	4927
@NP	guidance channel -LRB- 2.6-mm inner diameter , 3.0-mm outer diameter	4955
@NP	guidance channel	4955
@NP	2.6-mm inner diameter , 3.0-mm outer diameter	4973
@NP	2.6-mm inner diameter	4973
@NP	3.0-mm outer diameter	4996
@NP	T.	5031
@NP	Hazlett , CytoTherapeutics , Providence , RI -RRB- .	5034
@NP	Hazlett , CytoTherapeutics , Providence , RI -RRB-	5034
@NP	Hazlett	5034
@NP	CytoTherapeutics , Providence , RI -RRB-	5043
@NP	CytoTherapeutics	5043
@NP	Providence	5061
@NP	RI	5073
@NP	Thirty microliters	5078
@NP	SC suspended in a 60:40 -LRB- v/v -RRB- solution of DMEM/F -12 in Matrigel	5100
@NP	SC	5100
@NP	a 60:40 -LRB- v/v -RRB- solution of DMEM/F -12	5116
@NP	a 60:40 -LRB- v/v -RRB- solution	5116
@NP	DMEM/F -12	5142
@NP	Matrigel	5155
@NP	the channel	5182
@NP	windows	5202
@NP	Chondroitinase ABC -LRB- cABC ; Seikagaku America , East Falmouth , MA -RRB-	5211
@NP	Chondroitinase ABC	5211
@NP	cABC ; Seikagaku America	5231
@NP	cABC	5231
@NP	Seikagaku America	5237
@NP	East Falmouth , MA	5256
@NP	East Falmouth	5256
@NP	MA	5271
@NP	the SC bridge/host	5295
@NP	spinal cord interfaces	5314
@NP	osmotic mini-pumps -LRB- model 2002 ; Alzet , Cupertino , CA -RRB-	5343
@NP	osmotic mini-pumps	5343
@NP	model 2002 ; Alzet , Cupertino , CA	5363
@NP	model 2002	5363
@NP	Alzet , Cupertino , CA	5375
@NP	The pumps , connected to two catheters ,	5398
@NP	The pumps	5398
@NP	two catheters	5422
@NP	sterile 0.9 % NaCl	5447
@NP	the catheters	5473
@NP	the intervals between cABC injections	5500
@NP	the intervals	5500
@NP	cABC injections	5522
@NP	2 µL of 10 µg/mL cABC	5539
@NP	2 µL	5539
@NP	10 µg/mL cABC	5547
@NP	Injections of cABC into the catheters	5563
@NP	Injections	5563
@NP	cABC into the catheters	5577
@NP	cABC	5577
@NP	the catheters	5587
@NP	every other day for 4 weeks	5616
@NP	every other day	5616
@NP	4 weeks	5636
@NP	the catheter	5661
@NP	the pump under isoflurane anesthesia	5679
@NP	the pump	5679
@NP	isoflurane anesthesia	5694
@NP	The control group	5717
@NP	a transection	5744
@NP	Retrograde tracing	5764
@NP	Retrograde	5764
@NP	10 weeks postsurgery in treated and untreated rats	5797
@NP	10 weeks	5797
@NP	treated and untreated rats	5821
@NP	the tracing procedure	5853
@NP	a bilateral injection	5876
@NP	1 µL of 5 % FlouroGold -LRB- Chemicon International , Inc. , Temecula , CA -RRB-	5901
@NP	1 µL	5901
@NP	5 % FlouroGold -LRB- Chemicon International , Inc. , Temecula , CA -RRB-	5909
@NP	5 % FlouroGold	5909
@NP	Chemicon International	5924
@NP	Inc.	5948
@NP	Temecula , CA	5954
@NP	the Th13 segment of the spinal cord	5987
@NP	the Th13 segment	5987
@NP	the spinal cord	6007
@NP	A glass microelectrode with a tip diameter of 20 -- 30 µm	6024
@NP	A glass microelectrode	6024
@NP	a tip diameter of 20 -- 30 µm	6052
@NP	a tip diameter of 20	6052
@NP	a tip diameter	6052
@NP	20	6070
@NP	30 µm	6073
@NP	a Hamilton syringe	6096
@NP	the exposed spinal cord	6132
@NP	250 µm lateral to the midline and to a depth of ≈ 400 µm	6162
@NP	250 µm lateral	6162
@NP	the midline	6180
@NP	a depth of ≈ 400 µm	6199
@NP	a depth	6199
@NP	≈ 400 µm	6210
@NP	The electrode	6219
@NP	place	6245
@NP	1 min following injection	6255
@NP	1 min	6255
@NP	injection	6271
@NP	Two weeks later	6282
@NP	the animals	6299
@NP	pentobarbital -LRB- Euthanyl , Bimeda-MTC ; 70 mg/100 mg body weight -RRB-	6332
@NP	pentobarbital	6332
@NP	Euthanyl , Bimeda-MTC ; 70 mg/100 mg body weight	6347
@NP	Euthanyl , Bimeda-MTC	6347
@NP	70 mg/100 mg body weight	6369
@NP	70 mg/100	6369
@NP	mg body weight	6379
@NP	a cryostat	6415
@NP	horizontal sections of the spinal cord and cross-sections of the brains	6427
@NP	horizontal sections	6427
@NP	the spinal cord and cross-sections of the brains	6450
@NP	the spinal cord	6450
@NP	cross-sections of the brains	6470
@NP	cross-sections	6470
@NP	the brains	6488
@NP	25 m.	6517
@NP	The extent of the FG spreading	6524
@NP	The extent	6524
@NP	the FG spreading	6538
@NP	fluorescence microscopy	6574
@NP	neurons that did not regenerate into the caudal spinal cord	6619
@NP	neurons	6619
@NP	the caudal spinal cord	6656
@NP	animals where FG was detected closer than 2.5 mm caudal to the bridge	6680
@NP	animals	6680
@NP	FG	6694
@NP	closer than 2.5 mm caudal	6710
@NP	the bridge	6739
@NP	further analyzed	6759
@NP	further	6759
@NP	This	6777
@NP	a final group size of five animals in the combined treatment and four	6794
@NP	a final group size	6794
@NP	five animals in the combined treatment and four	6816
@NP	five animals	6816
@NP	the combined treatment and four	6832
@NP	the combined treatment	6832
@NP	four	6859
@NP	the control group	6867
@NP	an approach to explain the variability in our results	6889
@NP	the variability in our results	6912
@NP	the variability	6912
@NP	our results	6931
@NP	we	6944
@NP	the cross-section area of the tissue bridge at its narrowest point	6956
@NP	the cross-section area	6956
@NP	the tissue bridge at its narrowest point	6982
@NP	the tissue bridge	6982
@NP	its narrowest point	7003
@NP	light microscopy	7032
@NP	we	7061
@NP	the extent of the tissue on all the horizontal sections	7073
@NP	the extent	7073
@NP	the tissue on all the horizontal sections	7087
@NP	the tissue	7087
@NP	all the horizontal sections	7101
@NP	the bridge	7137
@NP	the average of these numbers	7163
@NP	the average	7163
@NP	these numbers	7178
@NP	the dorsal ventral extent	7195
@NP	the bridge -LRB- i.e. , number of section x 25 µm -RRB-	7224
@NP	the bridge	7224
@NP	section x 25 µm	7252
@NP	section	7252
@NP	25 µm	7262
@NP	An additional approach to explain the variability	7270
@NP	the variability	7304
@NP	variations	7334
@NP	the cABC-digested proteoglycans between the animals	7348
@NP	the cABC-digested proteoglycans	7348
@NP	the animals	7388
@NP	Fouad et al. -LRB- 2005 -RRB- and Moon et al. -LRB- 2001 -RRB-	7415
@NP	Fouad et al. -LRB- 2005 -RRB-	7415
@NP	Fouad	7415
@NP	et al. -LRB- 2005 -RRB-	7421
@NP	et al.	7421
@NP	2005	7429
@NP	Moon et al. -LRB- 2001 -RRB-	7439
@NP	Moon	7439
@NP	et al. -LRB- 2001 -RRB-	7444
@NP	et al.	7444
@NP	2001	7452
@NP	horizontal -LRB- 25 µm -RRB- sections	7470
@NP	25 µm	7482
@NP	the thoracic spinal cord	7506
@NP	the lesion	7543
@NP	mouse	7579
@NP	anti-chondroitin-4-sulfate monoclonal antibody	7585
@NP	C4S , 1:100 ; Chemicon International	7633
@NP	C4S	7633
@NP	1:100 ; Chemicon International	7638
@NP	1:100	7638
@NP	Chemicon International	7645
@NP	48 h	7673
@NP	secondary detection	7690
@NP	DAB vector kit -LRB- Vector Labs , Burlingame , CA -RRB-	7730
@NP	DAB vector kit	7730
@NP	Vector Labs	7746
@NP	Burlingame	7759
@NP	CA	7771
@NP	Staining -LRB- antibody exposure and visualization -RRB- of all slides	7776
@NP	Staining -LRB- antibody exposure and visualization -RRB-	7776
@NP	Staining	7776
@NP	antibody exposure and visualization	7786
@NP	antibody exposure	7786
@NP	visualization	7808
@NP	all slides	7826
@NP	Digital images	7867
@NP	200 µm	7903
@NP	the spinal cord rostral and caudal	7915
@NP	the spinal cord rostral	7915
@NP	caudal	7943
@NP	the bridge at 10x magnification	7953
@NP	the bridge	7953
@NP	10x magnification	7967
@NP	Images	7986
@NP	density	8011
@NP	Scion Image software -LRB- NIH -RRB-	8025
@NP	Scion Image software	8025
@NP	NIH	8047
@NP	results	8057
@NP	an average density measure -LRB- 2 images/rat -RRB-	8083
@NP	an average density measure	8083
@NP	2 images/rat	8111
@NP	The immuno-staining procedure against FG	8126
@NP	The immuno-staining procedure	8126
@NP	FG	8164
@NP	anti	8192
@NP	FG antibody -LRB- 1:1000 ; Chemicon International -RRB-	8197
@NP	FG antibody	8197
@NP	1:1000 ; Chemicon International	8210
@NP	1:1000	8210
@NP	Chemicon International	8218
@NP	a 10 % normal goat serum -LRB- NGS -RRB-	8249
@NP	a 10 % normal goat serum	8249
@NP	NGS	8274
@NP	step	8288
@NP	secondary antibody -LRB- Vector -RRB-	8307
@NP	secondary antibody	8307
@NP	Vector	8327
@NP	the instructions of the manufacturer	8348
@NP	the instructions	8348
@NP	the manufacturer	8368
@NP	the Nova Red kit -LRB- Vector -RRB-	8406
@NP	the Nova Red kit	8406
@NP	Vector	8424
@NP	cell bodies , consecutive cross-sections	8463
@NP	the brain and brainstem and horizontal sections	8511
@NP	the brain and brainstem	8511
@NP	horizontal sections	8539
@NP	the spinal cord	8567
@NP	light microscopy	8603
@NP	The location and number of Nova Red -- positive neurons	8621
@NP	The location and number	8621
@NP	Nova Red -- positive neurons	8648
@NP	Nova Red	8648
@NP	positive neurons	8657
@NP	each section with an overlaid grid	8695
@NP	each section	8695
@NP	an overlaid grid	8713
@NP	a stereotaxic atlas -LRB- Paxinos and Watson , 1986 -RRB-	8734
@NP	a stereotaxic atlas	8734
@NP	Paxinos and Watson , 1986	8755
@NP	Paxinos	8755
@NP	Watson , 1986	8767
@NP	Watson	8767
@NP	1986	8775
@NP	RESULTS	8783
@NP	1	8797
@NP	NUMBER AND LOCATION OF RETROGRADELY	8800
@NP	NUMBER AND LOCATION	8800
@NP	NUMBER	8800
@NP	LOCATION	8811
@NP	RETROGRADELY	8823
@NP	CELLS	8844
@NP	THE INDIVIDUAL ANIMALS FIG. 1	8853
@NP	THE INDIVIDUAL ANIMALS FIG.	8853
@NP	1	8882
@NP	FlouroGold-positive neurons in the spinal cord in an overview -LRB- A -RRB- .	8885
@NP	FlouroGold-positive neurons	8885
@NP	the spinal cord	8916
@NP	an overview -LRB- A -RRB-	8935
@NP	an overview	8935
@NP	A	8948
@NP	cells	8973
@NP	intermediate laminae of the thoracic spinal cord , rostral	9004
@NP	intermediate laminae	9004
@NP	the thoracic spinal cord , rostral	9028
@NP	the thoracic spinal cord	9028
@NP	rostral	9054
@NP	the lesion site	9065
@NP	higher magnification	9088
@NP	these cells	9110
@NP	the thoracic and the cervical spinal cord	9151
@NP	the thoracic	9151
@NP	the cervical spinal cord	9168
@NP	No cells	9194
@NP	the untreated animals	9217
@NP	lines	9247
@NP	graywhite matter interface	9262
@NP	FlouroGold-positive neurons in the brainstem	9290
@NP	FlouroGold-positive neurons	9290
@NP	the brainstem	9321
@NP	various nuclei	9349
@NP	the schematic in B -LRB- modified from Paxinos and Watson , 1986 -RRB-	9380
@NP	the schematic in B	9380
@NP	Paxinos and Watson , 1986	9414
@NP	Paxinos and Watson	9414
@NP	1986	9434
@NP	Examples	9441
@NP	labeled cells in various nuclei	9453
@NP	labeled cells	9453
@NP	various nuclei	9470
@NP	paragigantocellular -LRB- LPGi -RRB- , rostroventrolateral reticular	9495
@NP	paragigantocellular -LRB- LPGi -RRB-	9495
@NP	RVL	9554
@NP	raphe pallidus -LRB- RPa -RRB-	9560
@NP	raphe pallidus	9560
@NP	RPa	9576
@NP	lateral vestibular nucleus -LRB- LVe -RRB-	9586
@NP	lateral vestibular nucleus	9586
@NP	LVe	9614
@NP	C.	9632
@NP	The remaining abbreviations of brainstem nuclei	9635
@NP	The remaining abbreviations	9635
@NP	brainstem nuclei	9666
@NP	the result section	9699
@NP	the animals that received the combination treatment	9723
@NP	the animals	9723
@NP	the combination treatment	9749
@NP	we	9776
@NP	cell bodies	9806
@NP	the spinal cord rostral	9821
@NP	the lesion bridge/site	9848
@NP	the brainstem	9878
@NP	the highest number	9898
@NP	labeled cell bodies	9920
@NP	the thoracic spinal cord in laminae VII and VIII -LRB- Fig. 1A -RRB-	9943
@NP	the thoracic spinal cord in laminae VII	9943
@NP	the thoracic spinal cord	9943
@NP	laminae VII	9971
@NP	VIII -LRB- Fig. 1A -RRB-	9987
@NP	VIII	9987
@NP	Fig. 1A	9993
@NP	The cell bodies	10003
@NP	the central canal	10037
@NP	locations	10070
@NP	interneurons	10094
@NP	the lumbar spinal cord -LRB- Vavrek et al. , 2006 -RRB-	10121
@NP	the lumbar spinal cord	10121
@NP	Vavrek	10145
@NP	et al. , 2006	10152
@NP	et al.	10152
@NP	2006	10160
@NP	cell bodies	10175
@NP	size	10206
@NP	clusters	10227
@NP	These findings	10237
@NP	sharp contrast	10261
@NP	those in the transection-only group	10279
@NP	those	10279
@NP	the transection-only group	10288
@NP	no retrogradely labeled cell bodies	10322
@NP	no retrogradely	10322
@NP	cell bodies	10346
@NP	the treated group	10373
@NP	the numbers of the regenerated propriospinal interneurons	10392
@NP	the numbers	10392
@NP	the regenerated propriospinal interneurons	10407
@NP	PrI	10451
@NP	the rostral spinal cord	10459
@NP	increasing distance from the lesion site	10512
@NP	increasing distance	10512
@NP	the lesion site	10537
@NP	a rostral-caudal distance of 2 cm	10572
@NP	a rostral-caudal distance	10572
@NP	2 cm	10601
@NP	the mean number of the labeled PrI in the thoracic spinal cord in treated rats	10607
@NP	the mean number	10607
@NP	the labeled PrI in the thoracic spinal cord in treated rats	10626
@NP	the labeled PrI	10626
@NP	the thoracic spinal cord in treated rats	10645
@NP	the thoracic spinal cord	10645
@NP	treated rats	10673
@NP	238 ± 123 -LRB- mean ± SEM -RRB- and 12 ± 3.6 in the cervical spinal cord	10690
@NP	238 ± 123 -LRB- mean ± SEM -RRB-	10690
@NP	238 ±	10690
@NP	123 -LRB- mean ± SEM -RRB-	10696
@NP	123	10696
@NP	mean ± SEM	10701
@NP	12 ± 3.6 in the cervical spinal cord	10717
@NP	12 ± 3.6	10717
@NP	the cervical spinal cord	10729
@NP	FG-positive neurons	10755
@NP	the brainstem	10794
@NP	the animals that received the combined treatment -LRB- Fig. 1B , C -RRB-	10811
@NP	the animals	10811
@NP	the combined treatment	10837
@NP	Fig. 1B , C	10861
@NP	Fig. 1B	10861
@NP	C	10869
@NP	These results	10873
@NP	Table 1	10905
@NP	all animals	10931
@NP	the majority of labeled neurons in the brainstem	10944
@NP	the majority	10944
@NP	labeled neurons in the brainstem	10960
@NP	labeled neurons	10960
@NP	the brainstem	10979
@NP	the vestibular nuclei	11006
@NP	70 %	11035
@NP	the lateral vestibular nucleus -LRB- LVe -RRB-	11051
@NP	the lateral vestibular nucleus	11051
@NP	LVe	11083
@NP	median vestibular nucleus -LRB- MVe -RRB-	11089
@NP	median vestibular nucleus	11089
@NP	MVe	11116
@NP	superior vestibular nucleus -LRB- SuVe -RRB-	11122
@NP	superior vestibular nucleus	11122
@NP	SuVe	11151
@NP	spinal vestibular nucleus -LRB- SpVe -RRB-	11162
@NP	spinal vestibular nucleus	11162
@NP	SpVe	11189
@NP	18 % of all labeled	11202
@NP	18 %	11202
@NP	all labeled	11209
@NP	all	11209
@NP	neurons in the brainstem	11221
@NP	neurons	11221
@NP	the brainstem	11232
@NP	the reticular formation	11264
@NP	12 % in raphe nuclei	11298
@NP	12 %	11298
@NP	raphe nuclei	11305
@NP	No FG-positive cells	11319
@NP	the red nucleus and , in agreement	11360
@NP	the red nucleus	11360
@NP	agreement	11384
@NP	our earlier results -LRB- Fouad et al. , 2005 -RRB-	11399
@NP	our earlier results	11399
@NP	Fouad	11420
@NP	et al. , 2005	11426
@NP	et al.	11426
@NP	2005	11434
@NP	they	11450
@NP	the sensorimotor cortex	11464
@NP	localization of retrogradely traced brainstem neurons	12192
@NP	localization	12192
@NP	retrogradely traced brainstem neurons	12208
@NP	Figure 1C	12265
@NP	possible causes	12291
@NP	differences in the number of regenerated axons between the treated rats	12311
@NP	differences	12311
@NP	the number of regenerated axons between the treated rats	12326
@NP	the number	12326
@NP	regenerated axons between the treated rats	12340
@NP	regenerated axons	12340
@NP	the treated rats	12366
@NP	the area of a cross-section at the narrowest point of the tissue bridge	12384
@NP	the area	12384
@NP	a cross-section at the narrowest point of the tissue bridge	12396
@NP	a cross-section	12396
@NP	the narrowest point of the tissue bridge	12415
@NP	the narrowest point	12415
@NP	the tissue bridge	12438
@NP	0.26	12472
@NP	0.22	12478
@NP	0.35	12484
@NP	0.16	12490
@NP	0.29 mm2 in rats 1 , 3 , 6 , 8 , and 9 , respectively	12500
@NP	0.29 mm2	12500
@NP	rats 1 , 3 , 6 , 8 , and 9 , respectively	12512
@NP	rats 1	12512
@NP	3	12520
@NP	6 , 8 , and 9	12523
@NP	These results	12551
@NP	the animal with the largest bridge diameter	12575
@NP	the animal	12575
@NP	the largest bridge diameter	12591
@NP	the largest number of regenerated cells	12634
@NP	the largest number	12634
@NP	regenerated cells	12656
@NP	these data -LRB- bridge diameter and number of regenerated axons -RRB-	12692
@NP	these data	12692
@NP	bridge diameter and number of regenerated axons	12704
@NP	bridge diameter and number	12704
@NP	regenerated axons	12734
@NP	a significant r value	12754
@NP	r = 0.83	12787
@NP	r	12787
@NP	= 0.83	12789
@NP	Another factor	12798
@NP	the observed variability in the number of regenerated axons	12834
@NP	the observed variability	12834
@NP	the number of regenerated axons	12862
@NP	the number	12862
@NP	regenerated axons	12876
@NP	the degree of cABC digestion	12897
@NP	the degree	12897
@NP	cABC digestion	12911
@NP	the degree of cABC digestion	12942
@NP	the degree	12942
@NP	cABC digestion	12956
@NP	the rostral and caudal stump	12974
@NP	the rostral	12974
@NP	caudal stump	12990
@NP	positive correlation	13004
@NP	the number of regenerated cells	13043
@NP	the number	13043
@NP	regenerated cells	13057
@NP	thoracic spinal cord and the total number of regenerated cells	13083
@NP	thoracic spinal cord	13083
@NP	the total number of regenerated cells	13108
@NP	the total number	13108
@NP	regenerated cells	13128
@NP	the amount of cABC digestion -LRB- r values of 0	13151
@NP	the amount	13151
@NP	cABC digestion -LRB- r values of 0	13165
@NP	cABC	13165
@NP	digestion -LRB- r values of 0	13170
@NP	digestion	13170
@NP	r values of 0	13181
@NP	r values	13181
@NP	0	13193
@NP	9 and 0.8 , respectively -RRB- .	13196
@NP	9 and 0.8 , respectively -RRB-	13196
@NP	9	13196
@NP	0.8 , respectively -RRB-	13202
@NP	0.8	13202
@NP	DISCUSSION	13223
@NP	The main conclusion of this study	13234
@NP	The main conclusion	13234
@NP	this study	13257
@NP	the combined treatment	13276
@NP	Fouad	13318
@NP	et al. , 2005	13324
@NP	et al.	13324
@NP	2005	13332
@NP	the regeneration	13345
@NP	neurons other than serotonergic fibers through a tissue bridge	13365
@NP	neurons	13365
@NP	serotonergic fibers through a tissue bridge	13384
@NP	serotonergic fibers	13384
@NP	a tissue bridge	13412
@NP	the spinal cord caudal to a complete lesion	13433
@NP	the spinal cord caudal	13433
@NP	a complete lesion	13459
@NP	Retrograde tracing , which was caudal to the lesion ,	13478
@NP	Retrograde tracing	13478
@NP	Retrograde	13478
@NP	the lesion	13518
@NP	spinal interneurons rostral	13538
@NP	the lesion and various populations of brainstem neurons	13569
@NP	the lesion	13569
@NP	various populations of brainstem neurons	13584
@NP	various populations	13584
@NP	brainstem neurons	13607
@NP	cells	13634
@NP	animals that received a spinal cord transection but no treatment	13655
@NP	animals	13655
@NP	a spinal cord transection but no treatment	13677
@NP	a spinal cord transection	13677
@NP	no treatment	13707
@NP	This	13721
@NP	labeling of cells	13740
@NP	labeling	13740
@NP	cells	13752
@NP	axons	13773
@NP	the bridge	13800
@NP	intravascular tracer spreading or its diffusion	13822
@NP	intravascular tracer spreading	13822
@NP	its diffusion	13856
@NP	the cerebrospinal fluid	13875
@NP	An important finding	13900
@NP	the consistency among treated animals	13924
@NP	the consistency	13924
@NP	treated animals	13946
@NP	other words	13966
@NP	the majority of retrogradely labeled neurons	13979
@NP	the majority	13979
@NP	retrogradely labeled neurons	13995
@NP	the rostral spinal cord and the vestibular nuclei	14044
@NP	the rostral spinal cord	14044
@NP	the vestibular nuclei	14072
@NP	the outstanding regenerative capabilities of these neurons	14109
@NP	the outstanding regenerative capabilities	14109
@NP	these neurons	14154
@NP	The superior regenerative capacity of interneurons	14169
@NP	The superior regenerative capacity	14169
@NP	interneurons	14207
@NP	other studies	14236
@NP	various treatment approaches	14256
@NP	Menei	14286
@NP	et al. , 1998 ; Tsai et al. , 2005	14292
@NP	et al.	14292
@NP	1998 ; Tsai et al.	14300
@NP	1998	14300
@NP	Tsai et al.	14306
@NP	Tsai	14306
@NP	et al.	14311
@NP	2005	14319
@NP	Our results	14326
@NP	the idea	14351
@NP	the cell body 's proximity to the lesion	14365
@NP	the cell body 's proximity	14365
@NP	the cell body 's	14365
@NP	the lesion	14394
@NP	its potential	14416
@NP	Xu et al. , 1999	14445
@NP	Xu	14445
@NP	et al.	14448
@NP	1999	14456
@NP	the number of retrogradely labeled interneuron cell bodies	14466
@NP	the number	14466
@NP	retrogradely labeled interneuron cell bodies	14480
@NP	retrogradely	14480
@NP	interneuron cell bodies	14501
@NP	increasing distance from the bridge/lesion site	14540
@NP	increasing distance	14540
@NP	the bridge/lesion site	14565
@NP	the ability of vestibular neurons to regenerate in response to various therapies	14594
@NP	the ability	14594
@NP	vestibular neurons	14609
@NP	response	14645
@NP	various therapies	14657
@NP	earlier studies -LRB- Menei et al. , 1998 ; Tsai et al. , 2005 -RRB-	14691
@NP	earlier studies	14691
@NP	Menei	14708
@NP	et al. , 1998 ; Tsai et al. , 2005	14714
@NP	et al.	14714
@NP	1998 ; Tsai et al.	14722
@NP	1998	14722
@NP	Tsai et al.	14728
@NP	Tsai	14728
@NP	et al.	14733
@NP	2005	14741
@NP	these neurons	14759
@NP	this capacity	14781
@NP	Future characterization	14819
@NP	the injury response	14846
@NP	the expression	14877
@NP	regeneration-associated genes or cAMP levels	14895
@NP	vestibular neurons after injury and treatment	14947
@NP	vestibular neurons	14947
@NP	injury and treatment	14972
@NP	important clues	15008
@NP	the promotion of regeneration in other axonal systems	15028
@NP	the promotion	15028
@NP	regeneration in other axonal systems	15045
@NP	regeneration	15045
@NP	other axonal systems	15061
@NP	the population of neurons able to regenerate	15092
@NP	the population	15092
@NP	neurons able to regenerate	15110
@NP	neurons	15110
@NP	animals	15167
@NP	there	15176
@NP	a significant deviation in the number of labeled cells	15186
@NP	a significant deviation	15186
@NP	the number of labeled cells	15213
@NP	the number	15213
@NP	labeled cells	15227
@NP	This	15242
@NP	the complex nature	15274
@NP	the combined treatment	15296
@NP	variability	15325
@NP	multiple factors	15354
@NP	differences in the inflammatory response	15382
@NP	differences	15382
@NP	the inflammatory response	15397
@NP	OEC implantation	15445
@NP	the stumps	15467
@NP	discrepancies of CSPG digestion	15480
@NP	discrepancies	15480
@NP	CSPG digestion	15497
@NP	the mechanical stability of the channels	15516
@NP	the mechanical stability	15516
@NP	the channels	15544
@NP	Measurements of the bridge diameters	15558
@NP	Measurements	15558
@NP	the bridge diameters	15574
@NP	the bridge size	15609
@NP	account for the variability	15641
@NP	account	15641
@NP	the variability	15653
@NP	the biggest area	15673
@NP	the rat	15703
@NP	the highest number of labeled cells	15716
@NP	the highest number	15716
@NP	labeled cells	15738
@NP	the bridge in the rat with the smallest number of cells	15762
@NP	the bridge	15762
@NP	the rat with the smallest number of cells	15776
@NP	the rat	15776
@NP	the smallest number of cells	15789
@NP	the smallest number	15789
@NP	cells	15812
@NP	that of the others , indicating that other factors are involved	15835
@NP	that	15835
@NP	the others	15843
@NP	other factors	15871
@NP	Another possible reason for more or less successful regeneration	15899
@NP	Another possible reason	15899
@NP	more or less successful regeneration	15927
@NP	the degree	15967
@NP	proteoglycan digestion	15981
@NP	the tissue penetration of the administered cABC	16022
@NP	the tissue penetration	16022
@NP	the administered cABC	16048
@NP	The finding	16071
@NP	the rat with the highest number of regenerated axons	16092
@NP	the rat	16092
@NP	the highest number of regenerated axons	16105
@NP	the highest number	16105
@NP	regenerated axons	16127
@NP	the digestion for proteoglycans	16146
@NP	the digestion	16146
@NP	proteoglycans	16164
@NP	this suggestion	16200
@NP	The results of the current study	16217
@NP	The results	16217
@NP	the current study	16232
@NP	a better understanding	16256
@NP	the mechanisms	16282
@NP	locomotor recovery following combined treatment	16310
@NP	locomotor recovery	16310
@NP	combined treatment	16339
@NP	Fouad	16359
@NP	et al. , 2005	16365
@NP	et al.	16365
@NP	2005	16373
@NP	the results	16389
@NP	serotonergic fibers	16414
@NP	the caudal stump of the spinal cord	16474
@NP	the caudal stump	16474
@NP	the spinal cord	16494
@NP	the spinal cord caudal	16533
@NP	the lesion	16559
@NP	These fibers	16571
@NP	great candidates for promoting locomotor recovery	16593
@NP	great candidates	16593
@NP	locomotor recovery	16624
@NP	serotonin	16647
@NP	lower thresholds for the initiation of locomotor activity	16682
@NP	lower thresholds	16682
@NP	the initiation of locomotor activity	16703
@NP	the initiation	16703
@NP	locomotor activity	16721
@NP	addition	16744
@NP	the grafting of serotonergic cells into the lumbar spinal cord on its own	16754
@NP	the grafting	16754
@NP	serotonergic cells into the lumbar spinal cord on its own	16770
@NP	serotonergic cells	16770
@NP	the lumbar spinal cord on its own	16794
@NP	the lumbar spinal cord	16794
@NP	its own	16820
@NP	locomotor recovery -LRB- Ribotta et al. , 2000 -RRB-	16854
@NP	locomotor recovery	16854
@NP	Ribotta	16874
@NP	et al. , 2000	16882
@NP	et al.	16882
@NP	2000	16890
@NP	the study by Fouad et al. -LRB- 2005 -RRB-	16909
@NP	the study	16909
@NP	Fouad et al. -LRB- 2005 -RRB-	16922
@NP	Fouad et al.	16922
@NP	Fouad	16922
@NP	et al.	16928
@NP	2005	16936
@NP	recovery	16943
@NP	the number of regenerated serotonergic fibers	16975
@NP	the number	16975
@NP	regenerated serotonergic fibers	16989
@NP	these axons	17044
@NP	a major contributor to the recovery	17059
@NP	a major contributor	17059
@NP	the recovery	17082
@NP	vestibulospinal fibers	17106
@NP	another group of fibers that showed superior regenerative capabilities	17133
@NP	another group	17133
@NP	fibers that showed superior regenerative capabilities	17150
@NP	fibers	17150
@NP	superior regenerative capabilities	17169
@NP	Neurons of the vestibulospinal tract	17205
@NP	Neurons	17205
@NP	the vestibulospinal tract	17216
@NP	locomotor activity	17273
@NP	extensor tone	17327
@NP	they	17351
@NP	the initiation of stepping movements -LRB- Mori et al. , 1992 -RRB-	17377
@NP	the initiation	17377
@NP	movements -LRB- Mori et al. , 1992 -RRB-	17404
@NP	movements	17404
@NP	Mori	17415
@NP	et al. , 1992	17420
@NP	et al.	17420
@NP	1992	17428
@NP	the major tract responsible for initiating stepping in rodents and cats	17444
@NP	the major tract	17444
@NP	rodents and cats	17499
@NP	the reticulospinal tract -LRB- Jordan , 1998 -RRB-	17519
@NP	the reticulospinal tract	17519
@NP	Jordan	17545
@NP	1998	17553
@NP	we	17573
@NP	the reticulospinal tract	17587
@NP	significantly fewer fibers	17624
@NP	the caudal spinal cord than , for example , the vestibulospinal tract	17656
@NP	the caudal spinal cord	17656
@NP	example	17689
@NP	the vestibulospinal tract	17698
@NP	we	17725
@NP	fibers from the reticulospinal tract	17745
@NP	fibers	17745
@NP	the reticulospinal tract	17757
@NP	their projection	17795
@NP	lesions -LRB- Ballermann and Fouad , 2006 -RRB-	17839
@NP	lesions	17839
@NP	Ballermann and Fouad , 2006	17848
@NP	Ballermann and Fouad	17848
@NP	2006	17870
@NP	a relatively small number of reticulospinal tract fibers	17883
@NP	a relatively small number	17883
@NP	reticulospinal tract fibers	17912
@NP	strong impact	17960
@NP	the activation of pattern generating networks	17977
@NP	the activation	17977
@NP	pattern generating networks	17995
@NP	locomotor movements	18046
@NP	recent studies	18076
@NP	lesioned descending tracts -LRB- i.e. , the CST -RRB-	18104
@NP	lesioned descending tracts	18104
@NP	i.e. , the CST	18132
@NP	i.e.	18132
@NP	the CST	18138
@NP	propriospinal interneurons	18164
@NP	Bareyre	18192
@NP	et al. , 2004 ; Vavrek et al. , 2006	18200
@NP	et al.	18200
@NP	2004 ; Vavrek et al.	18208
@NP	2004	18208
@NP	Vavrek et al.	18214
@NP	Vavrek	18214
@NP	et al.	18221
@NP	2006	18229
@NP	not only regenerated fibers	18249
@NP	functional recovery	18295
@NP	pathways	18334
@NP	the relatively large population of regenerated interneurons	18364
@NP	the relatively large population	18364
@NP	regenerated interneurons	18399
@VP	is limited by inhibitors associated with myelin and the glial scar	245
@VP	limited by inhibitors associated with myelin and the glial scar	248
@VP	associated with myelin and the glial scar	270
@VP	To overcome these inhibitors	313
@VP	overcome these inhibitors	316
@VP	will be required	363
@VP	be required	368
@VP	required	371
@VP	bridging the lesion with Schwann cell -LRB- SC -RRB-	468
@VP	promoted regeneration of serotonergic fibers into the lumbar spinal cord	610
@VP	improved locomotor recovery	738
@VP	To complement these findings	767
@VP	complement these findings	770
@VP	were able to regenerate into the caudal spinal cord	888
@VP	to regenerate into the caudal spinal cord	898
@VP	regenerate into the caudal spinal cord	901
@VP	were able to regenerate across the SC bridge and into the caudal spinal cord	1210
@VP	to regenerate across the SC bridge and into the caudal spinal cord	1220
@VP	regenerate across the SC bridge and into the caudal spinal cord	1223
@VP	Treated	1288
@VP	were highest in the thoracic spinal cord and the lateral vestibular nucleus	1434
@VP	to regenerate	1592
@VP	regenerate	1595
@VP	may provide valuable clues in the design of future treatment approaches	1606
@VP	provide valuable clues in the design of future treatment approaches	1610
@VP	are unable to regenerate following injury	1745
@VP	to regenerate following injury	1756
@VP	regenerate following injury	1759
@VP	To overcome the inhibitory environment of the injured spinal cord	2046
@VP	overcome the inhibitory environment of the injured spinal cord	2049
@VP	to provide a growth permissive bridge for regenerating axons	2116
@VP	provide a growth permissive bridge for regenerating axons	2119
@VP	resulted in significantly improved hind limb function	2510
@VP	increased the numbers of myelinated axons within the SC bridges	2565
@VP	promoted regeneration of serotonergic fibers into the lumbar spinal cord	2634
@VP	correlation between recovery and regenerated serotonergic fibers	2729
@VP	correlation between recovery	2729
@VP	regenerated serotonergic fibers	2762
@VP	suggested that also other fiber types were capable of regeneration	2794
@VP	were capable of regeneration	2832
@VP	failed to provide evidence for that possibility	2989
@VP	to provide evidence for that possibility	2996
@VP	provide evidence for that possibility	2999
@VP	repeat the combined treatment	3085
@VP	injecting a retrograde tracer caudal to the injury	3229
@VP	were performed according to Fouad	3305
@VP	performed according to Fouad	3310
@VP	using adult female Fischer rats -LRB- Charles River , Wilmington , MA -RRB-	3354
@VP	was approved by local authorities	3434
@VP	approved by local authorities	3438
@VP	were prepared as described previously -LRB- Fouad et al. , 2005 -RRB-	3481
@VP	described previously -LRB- Fouad et al. , 2005 -RRB-	3498
@VP	Purified cultures of OEG	3646
@VP	modified from one described previously	3781
@VP	described previously	3799
@VP	Cultured SCs or OEG	3848
@VP	were harvested in DMEM/F -12 medium	3868
@VP	harvested in DMEM/F -12 medium	3873
@VP	were trypsinized to remove them from the dishes	3932
@VP	trypsinized to remove them from the dishes	3937
@VP	to remove them from the dishes	3949
@VP	remove them from the dishes	3952
@VP	were counted using a hemocytometer	3995
@VP	counted using a hemocytometer	4000
@VP	using a hemocytometer	4008
@VP	grafting	4150
@VP	received a total of 5 x 10 ^ 6 SCs for transplantation	4172
@VP	were resuspended in aliquots of 4 µL of DMEM/F -12 medium containing 4	4230
@VP	resuspended in aliquots of 4 µL of DMEM/F -12 medium containing 4	4235
@VP	containing 4	4287
@VP	10 ⌃ 5 cells immediately before spinal cord injection	4302
@VP	diluted in H2O ; Sabex , Boucherville , Quebec , Canada	4543
@VP	encompassing Th8	4685
@VP	was removed	4702
@VP	removed	4706
@VP	containing ≈ 105 OEG in DMEM/F -12	4754
@VP	was grafted into each stump	4787
@VP	grafted into each stump	4791
@VP	suspended in a 60:40 -LRB- v/v -RRB- solution of DMEM/F -12 in Matrigel	5103
@VP	was injected into the channel through windows	5164
@VP	injected into the channel through windows	5168
@VP	using osmotic mini-pumps -LRB- model 2002 ; Alzet , Cupertino , CA -RRB-	5337
@VP	connected to two catheters	5409
@VP	disconnecting the catheter from the pump under isoflurane anesthesia	5647
@VP	received a transection only	5735
@VP	tracing	5775
@VP	was performed 10 weeks postsurgery in treated and untreated rats	5783
@VP	performed 10 weeks postsurgery in treated and untreated rats	5787
@VP	treated	5821
@VP	was performed into the Th13 segment of the spinal cord	5968
@VP	performed into the Th13 segment of the spinal cord	5972
@VP	was mounted onto a Hamilton syringe	6079
@VP	mounted onto a Hamilton syringe	6083
@VP	remained in place for 1 min following injection	6233
@VP	perfused	6399
@VP	Using a cryostat	6409
@VP	were sectioned at 25 m.	6499
@VP	sectioned at 25 m.	6504
@VP	was measured using fluorescence microscopy	6555
@VP	measured using fluorescence microscopy	6559
@VP	using fluorescence microscopy	6568
@VP	To avoid tracing of neurons that did not regenerate into the caudal spinal cord	6599
@VP	avoid tracing of neurons that did not regenerate into the caudal spinal cord	6602
@VP	tracing of neurons that did not regenerate into the caudal spinal cord	6608
@VP	did not regenerate into the caudal spinal cord	6632
@VP	regenerate into the caudal spinal cord	6640
@VP	was detected closer than 2.5 mm caudal to the bridge	6697
@VP	detected closer than 2.5 mm caudal to the bridge	6701
@VP	were not further analyzed	6750
@VP	analyzed	6767
@VP	to explain the variability in our results	6901
@VP	explain the variability in our results	6904
@VP	using light microscopy	7026
@VP	to explain the variability	7293
@VP	explain the variability	7296
@VP	containing the lesion	7532
@VP	were immunostained with mouse	7555
@VP	immunostained with mouse	7560
@VP	followed by secondary detection	7678
@VP	visualized with DAB vector kit -LRB- Vector Labs , Burlingame , CA -RRB-	7714
@VP	was performed simultaneously	7837
@VP	performed simultaneously	7841
@VP	were analyzed for density using Scion Image software -LRB- NIH -RRB-	7993
@VP	analyzed for density using Scion Image software -LRB- NIH -RRB-	7998
@VP	using Scion Image software -LRB- NIH -RRB-	8019
@VP	were expressed as an average density measure -LRB- 2 images/rat -RRB-	8065
@VP	expressed as an average density measure -LRB- 2 images/rat -RRB-	8070
@VP	formed by using anti	8176
@VP	using anti	8186
@VP	visualized with the Nova Red kit -LRB- Vector -RRB-	8390
@VP	were examined using light microscopy	8583
@VP	examined using light microscopy	8588
@VP	using light microscopy	8597
@VP	TABLE 1	8791
@VP	LABELED CELLS IN THE INDIVIDUAL ANIMALS FIG. 1	8836
@VP	Retrogradely labeled	8952
@VP	were clearly identifiable in the thoracic and the cervical spinal cord	9122
@VP	were found in the untreated animals	9203
@VP	found in the untreated animals	9208
@VP	Dashed	9240
@VP	indicate graywhite matter interface	9253
@VP	modified from Paxinos and Watson , 1986	9400
@VP	are shown in C.	9619
@VP	shown in C.	9623
@VP	can be found in the result section	9683
@VP	be found in the result section	9687
@VP	found in the result section	9690
@VP	received the combination treatment	9740
@VP	descending to the lumbar spinal cord -LRB- Vavrek et al. , 2006 -RRB-	10107
@VP	Labeled	10167
@VP	were comparable in size and appeared in clusters	10187
@VP	were comparable in size	10187
@VP	appeared in clusters	10215
@VP	labeled cell bodies	10338
@VP	were found	10358
@VP	found	10363
@VP	decreased progressively with increasing distance from the lesion site	10483
@VP	counted over a rostral-caudal distance of 2 cm	10559
@VP	was 238 ± 123 -LRB- mean ± SEM -RRB- and 12 ± 3.6 in the cervical spinal cord	10686
@VP	received the combined treatment	10828
@VP	are summarized in Table 1	10887
@VP	summarized in Table 1	10891
@VP	labeled	11213
@VP	were found within the reticular formation and about 12 % in raphe nuclei	11246
@VP	found within the reticular formation and about 12 % in raphe nuclei	11251
@VP	were they found in the sensorimotor cortex	11445
@VP	found in the sensorimotor cortex	11455
@VP	Labeling	12179
@VP	are illustrated in Figure 1C	12246
@VP	illustrated in Figure 1C	12250
@VP	presented the largest number of regenerated cells	12624
@VP	was found -LRB- r = 0.83 -RRB-	12776
@VP	found -LRB- r = 0.83 -RRB-	12780
@VP	possibly involved in the observed variability in the number of regenerated axons	12813
@VP	is the degree of cABC digestion	12894
@VP	examining the degree of cABC digestion at the rostral and caudal stump	12932
@VP	is that the combined treatment presented earlier	13268
@VP	presented earlier	13299
@VP	tracing	13489
@VP	was caudal to the lesion	13504
@VP	Labeled	13626
@VP	were absent in animals that received a spinal cord transection but no treatment	13640
@VP	received a spinal cord transection but no treatment	13668
@VP	is the consistency among treated animals	13921
@VP	demonstrating the outstanding regenerative capabilities of these neurons	14095
@VP	determines its potential to regenerate -LRB- Xu et al. , 1999 -RRB-	14405
@VP	to regenerate -LRB- Xu et al. , 1999 -RRB-	14430
@VP	regenerate -LRB- Xu et al. , 1999 -RRB-	14433
@VP	labeled interneuron cell bodies	14493
@VP	decreased with increasing distance from the bridge/lesion site	14525
@VP	to regenerate in response to various therapies	14628
@VP	regenerate in response to various therapies	14631
@VP	exhibit this capacity	14773
@VP	remains to be resolved	14795
@VP	to be resolved	14803
@VP	be resolved	14806
@VP	resolved	14809
@VP	to regenerate	15123
@VP	regenerate	15126
@VP	was fairly consistent between animals	15137
@VP	was a significant deviation in the number of labeled cells	15182
@VP	caused by multiple factors , including differences in the inflammatory response	15344
@VP	especially following OEC implantation into the stumps	15424
@VP	was found in the rat with the highest number of labeled cells	15690
@VP	found in the rat with the highest number of labeled cells	15694
@VP	is comparable to that of the others , indicating that other factors are involved	15818
@VP	indicating that other factors are involved	15855
@VP	are involved	15885
@VP	depends on the tissue penetration of the administered cABC	16011
@VP	was highest	16178
@VP	supports this suggestion	16191
@VP	promote locomotor recovery following combined treatment	16302
@VP	were reported to regenerate into the caudal stump of the spinal cord	16441
@VP	reported to regenerate into the caudal stump of the spinal cord	16446
@VP	to regenerate into the caudal stump of the spinal cord	16455
@VP	regenerate into the caudal stump of the spinal cord	16458
@VP	managed to enter the spinal cord caudal to the lesion	16516
@VP	to enter the spinal cord caudal to the lesion	16524
@VP	enter the spinal cord caudal to the lesion	16527
@VP	promoting locomotor recovery	16614
@VP	been demonstrated to lower thresholds for the initiation of locomotor activity	16661
@VP	demonstrated to lower thresholds for the initiation of locomotor activity	16666
@VP	has been shown to improve locomotor recovery -LRB- Ribotta et al. , 2000 -RRB-	16828
@VP	been shown to improve locomotor recovery -LRB- Ribotta et al. , 2000 -RRB-	16832
@VP	shown to improve locomotor recovery -LRB- Ribotta et al. , 2000 -RRB-	16837
@VP	to improve locomotor recovery -LRB- Ribotta et al. , 2000 -RRB-	16843
@VP	improve locomotor recovery -LRB- Ribotta et al. , 2000 -RRB-	16846
@VP	eliminating these axons as a major contributor to the recovery	17032
@VP	are another group of fibers that showed superior regenerative capabilities	17129
@VP	showed superior regenerative capabilities	17162
@VP	to modulate locomotor activity and to significantly contribute to extensor tone	17261
@VP	to modulate locomotor activity	17261
@VP	modulate locomotor activity	17264
@VP	to significantly contribute to extensor tone	17296
@VP	contribute to extensor tone	17313
@VP	stepping movements -LRB- Mori et al. , 1992 -RRB-	17395
@VP	initiating stepping in rodents and cats	17476
@VP	stepping in rodents and cats	17487
@VP	is the reticulospinal tract -LRB- Jordan , 1998 -RRB-	17516
@VP	to compensate for lesions -LRB- Ballermann and Fouad , 2006 -RRB-	17821
@VP	compensate for lesions -LRB- Ballermann and Fouad , 2006 -RRB-	17824
@VP	are orchestrating locomotor movements	18028
@VP	orchestrating locomotor movements	18032
@VP	suggest that , not only regenerated fibers may contribute to functional recovery	18235
@VP	may contribute to functional recovery	18277
@VP	contribute to functional recovery	18281
@VP	could contribute via the relatively large population of regenerated interneurons	18343
@VP	contribute via the relatively large population of regenerated interneurons	18349
